CRMP1 and Huntington disease: The neuroprotective effect of (S)-LCM, which binds to CRMP2 and prevents its phosphorylation at Thr 509/514 and Ser 522 [50,51], but does not affect CRMP2 phosphorylation at Tyr 32 or Thr 555, or Drp1 phosphorylation at Ser 616, suggests that the changes in CRMP2 phosphorylation at Thr 509/514 and Ser 522 may play a major role in HD neuropathology and, consequently, could be a valid target for therapeutic intervention.